PUT - SPRINTER OPEN END - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 02:01:37 2024-07-05 pm EDT | ||
| 3.96 EUR | -1.00% |
|
| Current month | +3.66% | ||
| 1 month | -6.82% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 3.96 | -1.00% |
| 24-07-04 | 4 | +0.50% |
| 24-07-03 | 3.98 | +2.84% |
| 24-07-02 | 3.87 | +1.31% |
| 24-07-01 | 3.82 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update July 05, 2024 at 02:01 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VU5B06 |
| ISIN | DE000VU5B064 |
| Date issued | 2023-03-24 |
| Strike | 109.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.36 € |
|---|---|
| Lowest since issue | 2.1 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
66.69
USD
Average target price
82.97
USD
Spread / Average Target
+24.41%
- Stock Market
- Certificates
- Certificat
